‘Huang Qi Elixir’ for proteinuria in patients with diabetic nephropathy: a study protocol for a randomized controlled pilot trial

Trials

Sen Zhong¹  Fei Wang³  Ping Fu⁴  Xue Feng Ye⁵  James B Jordan²  Fang Liu⁴  Xiang Tu¹ 

[1] National Traditional Chinese Medicine Clinical Research Base/Teaching Hospital of Chengdu University of Traditional Chinese Medicine (Traditional Chinese Medicine Hospital of Sichuan Province), Chengdu, Sichuan Province 610072, China;Private Practice, 453 Cerrillos Rd., Bldg. E, Santa Fe, NM 87501, USA;Department of Gerontology, Teaching Hospital of Chengdu University of Traditional Chinese Medicine (Traditional Chinese Medicine Hospital of Sichuan Province), Chengdu, Sichuan Province 610072, China;Division of Nephrology, West China Hospital of Sichuan University, Chengdu, Sichuan Province 610041, China;Department of Nephrology, Teaching Hospital of Chengdu University of Traditional Chinese Medicine (Traditional Chinese Medicine Hospital of Sichuan Province), Chengdu, Sichuan Province 610072, China

关键词: Pilot trial;    Clinical trials;    Proteinuria;    Diabetic nephropathy;    Huang Qi Elixir;    Traditional Chinese Medicine;   

Others  :  1093389
DOI  :  10.1186/1745-6215-14-223

 received in 2012-11-27, accepted in 2013-07-03,  发布年份 2013

【 摘 要 】

Background

Diabetic nephropathy (DN) is the major complication of diabetes; proteinuria is the hall mark of DN. Currently, the treatment for proteinuria is mainly limited to angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs). According to Traditional Chinese Medicine (TCM) theory, Chinese medicinals ‘securing essence and tonifying the kidney’ may be appropriate for proteinuria. The most promising Chinese medicinals and formulae are introduced in the present study to form a potent formula for DN proteinuria. To make oral administration convenient, the formula will be processed in the form of granules.

Methods/design

A randomized, multi-center pilot trial will be conducted. Forty eight participants with DN will be randomly assigned to one of four treatment groups:

1. A granule group, at 10 grams, three times daily (G10 group, n = 12);

2. A granule group, at 20 grams, three times daily (G20 group, n = 12);

3. A decoction group (D group, n = 12); and

4. An irbesartan group (Aprovel group, n = 12).

The following outcome measures will be used: the percentage change of the albumin-to-creatinine ratio; and the changes in serum creatinine, glomerular filtration rate, fasting plasma glucose and hemoglobulin from baseline to the end of the trial.

Discussion

It is notable that most published clinical trials which assessed the efficacy of TCM on DN were of poor methodology and, therefore, their results have been invalidated. It is necessary to carry out well-designed clinical trials to provide sound evidence. The present trial is a study with potentially great value, for it will provide the parameters for future randomized, placebo-controlled, clinical trials with large sample sizes.

Trial registration

The trial is registered on the Chinese Clinical Trial Registry: ChiCTR-TRC-12002718 (http://www.chictr.org/cn/proj/show.aspx?proj=3820 webcite).

【 授权许可】

   
2013 Tu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Jie Z, Xiang HD: Epidemiological analysis for diabetic nephropathy among patients with type 2 diabetes mellitus in Beijing City. Bull Med Res 2004, 33:10-12.
• [2]Wu CG: Basic Theory of Traditional Chinese Medicine. Shanghai: Publishing House of Shanghai University of Traditional Chinese Medicine; 2006.
• [3]Murussi M, Murussi N, Campagnolo N, Silveiro SP: Early detection of diabetic nephropathy. Arq Bras Endocrinol Metabol 2008, 52:442-451.
• [4]Fernandez-Juárez G, Barrio V, de Vinuesa SG, Goicoechea M, Praga M, Luño J: Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials. J Am Soc Nephrol 2006, 17(Suppl 3):S250-S254.
• [5]Vejakama P, Thakkinstian A, Lertrattananon D, Ingsathit A, Ngarmukos C, Attia J: Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia 2012, 55:566-578.
• [6]Zhang J, Xie X, Li C, Fu P: Systematic review of the renal protective effect of Astragalus membranaceus (root) on diabetic nephropathy in animal models. J Ethnopharmacol 2009, 126:189-196.
• [7]Hong XP, Zhang XZ, He XL, Huang XZ, Chen HR, Wang YZ: Effect of Astragalus mongholicus on renal gene expression profile in mice with diabetic nephropathy. Zhongguo Zhong Yao Za Zhi 2008, 33:676-680.
• [8]Hua F, Mo CW, Chen Qun XZW, Jing W, Hua C, Sun ZQ: A systematic review of Traditional Chinese Medicine for the treatment of diabetic nephropathy. J Jiangxi Univ TCM 2008, 20:45-48.
• [9]Duan FJ: Formulae of Traditional Chinese Medicine. Shanghai: Shanghai Scientific & Technical Publishers; 2000:154-155.
• [10]Tang D, He B, Zheng ZG, Wang RS, Gu F, Duan TT, Cheng HQ, Zhu Q: Inhibitory effects of two major isoflavonoids in Radix Astragali on high glucose-induced mesangial cell proliferation and AGEs-induced endothelial cells apoptosis. Planta Med 2011, 77:729-732.
• [11]Zhang YW, Wu CY, Cheng JT: Merit of Astragalus polysaccharide in the improvement of early diabetic nephropathy with an effect on mRNA expressions of NF-kappaB and IkappaB in renal cortex of streptozotoxin-induced diabetic rats. J Ethnopharmacol 2007, 114:387-392.
• [12]Liu YH, Yang L, Liu J: Clinical observation on treatment of early diabetic nephropathy by milkvetch injection combined with captopril. Zhongguo Zhong Xi Yi Jie He Za Zhi 2005, 25:993-995.
• [13]Liu S, Tang LQ, Chen LM, Chen XQ, Zhang ST, Wei Y: Effect of compound Rhizoma Coptidis capsule on expression of transforming growth factor-beta1 and type IV collagen proteins in renal tissue of diabetic rats with nephropathy. Zhongguo Zhong Yao Za Zhi 2008, 33:68-72.
• [14]Sun WS, Wu XL, Qiao CL: Clinical study on effect of tongluo capsule in treating diabetic nephropathy caused chronic renal failure. Zhongguo Zhong Xi Yi Jie He Za Zhi 2004, 24:704-706.
• [15]Bian F, Zhao P, Zhang Z: Clinical study on treatment of incipient diabetic nephropathy by integrated traditional Chinese and Western medicine. Zhongguo Zhong Xi Yi Jie He Za Zhi 2000, 20:335-337.
• [16]Liu YH, Tian HM: Effect of Astragaulus membranaceus on diabetic nephropathy: a systematic review. Chin J Evidence-based Med 2007, 7:715-727.
• [17]Wang Feng WHM: Xuezhikang for diabetic kidney disease: a systematic review of randomized controlled trials. Chin J Evidence-based Med 2009, 9:63-70.